Orgenesis INC

Orgenesis Inc. stockholders approved an amendment to increase authorized common stock from 14.58 million to 150 million shares.

Orgenesis Inc. announced the election of two new directors to its Board and the appointment of a new Chief Financial Officer, effective March 10, 2026.

Orgenesis Inc. has issued 3.29 million non-transferable warrants to Alpha Prosperity Fund SPC as part of a previously disclosed convertible loan agreement.

Orgenesis Inc. subsidiary Theracell Laboratories IKE secured a $1 million convertible loan and a $10 million credit facility, but faces significant potential equity dilution and loss of control.

Ashish Nanda has resigned from the Board of Directors of Orgenesis Inc., effective immediately, with no reported disagreements.

Orgenesis Inc. announced the immediate resignations of its Chief Financial Officer and three board directors, citing no disagreements with management.

Orgenesis Inc. reported its Q3 2024 results, marked by a Nasdaq delisting, the reconsolidation of Octomera, and various strategic transactions.

Orgenesis Inc. reported its financial results for the second quarter of 2024, highlighting a revenue increase but also ongoing challenges with profitability and Nasdaq compliance.

Orgenesis Inc. reported its first quarter 2024 results, marked by a net loss, the reconsolidation of Octomera, and ongoing efforts to address financial and listing challenges.

Orgenesis Inc. has amended its Q3 2023 report to correct accounting errors related to revenue recognition, credit losses, and equity investments.

Orgenesis Inc. has amended its Q2 2023 quarterly report to restate financials due to errors in revenue recognition and credit loss accounting.

Orgenesis Inc. has amended its Q1 2023 quarterly report to restate financial statements due to errors in revenue recognition and credit loss accounting.

Orgenesis Inc. reports substantial doubt about its ability to continue as a going concern, with significant net losses and a worsening working capital deficit, following its delisting from Nasdaq.

Orgenesis Inc. released its 2023 annual report, highlighting a significant decrease in revenue and ongoing financial uncertainties.

Director Yaron Adler of Orgenesis Inc. was granted 1,750 stock options under the company's 2017 Equity Incentive Plan.

Director Adam Pelavin of Orgenesis Inc. was granted stock options under the company's 2017 Equity Incentive Plan.

Director Ashish Nanda of Orgenesis Inc. was granted 1,835 stock options under the company's 2017 Equity Incentive Plan.

Director Santhosh Nagaraj of Orgenesis Inc. was granted stock options under the company's 2017 Equity Incentive Plan.

Director Itzhak Vider of Orgenesis Inc. was granted 1,500 stock options on December 12, 2024, which vest in one year.

Director Bhalaji Jagannathan of Orgenesis Inc. was granted stock options under the company's 2017 Equity Incentive Plan.

Orgenesis Inc. is holding a special meeting on May 27, 2026, to vote on increasing authorized shares, approving a convertible loan agreement, and ratifying auditor appointment.

Orgenesis Inc. has filed a definitive proxy statement with the SEC.

Orgenesis Inc. is holding its 2024 annual meeting of stockholders virtually on June 27, 2024, to elect directors, approve an amendment to the 2017 Equity Incentive Plan, and ratify the appointment of its independent registered public accounting firm.

Neurocords LLC and Ariel Malik have disclosed a significant passive ownership stake of 18.84% in Orgenesis, Inc. through a Schedule 13G filing.